ONCOTHERAPY SCIENCE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18 JPY | +5.88% |
|
-5.26% | -21.74% |
| 04-29 | Poland's Tusk calls prosecutor over potential Orlen scandal | RE |
| 04-22 | OncoTherapy Science, Inc. cancelled the transaction announced on April 5, 2024 | CI |
| Sales 2022 | 1.15B 7.41M 592M | Sales 2023 | 1.13B 7.29M 582M | Capitalization | 9.05B 58.23M 4.65B |
|---|---|---|---|---|---|
| Net income 2022 | -2.57B -16.53M -1.32B | Net income 2023 | -1.12B -7.19M -574M | EV / Sales 2022 | 9.94 x |
| Net cash position 2022 | 1.84B 11.81M 943M | Net cash position 2023 | 1.12B 7.18M 573M | EV / Sales 2023 | 7 x |
| P/E ratio 2022 |
-5.03
x | P/E ratio 2023 |
-8.1
x | Employees | 60 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 81.45% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +5.88% | ||
| 1 week | -5.26% | ||
| Current month | -10.00% | ||
| 1 month | -10.00% | ||
| 3 months | -10.00% | ||
| 6 months | -35.71% | ||
| Current year | -21.74% |
1 week
16.00
20.00
1 month
16.0021.00
Current year
16.0024.00
1 year
16.0045.00
3 years
16.00126.00
5 years
16.00229.00
10 years
16.00736.00
| Managers | Title | Age | Since |
|---|---|---|---|
Junichi Shimada
PSD | President | 62 | 30/11/21 |
Zehyon Paku
CTO | Chief Tech/Sci/R&D Officer | 48 | 30/06/17 |
Yuichi Komine
BRD | Director/Board Member | 52 | 31/05/08 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yuichi Komine
BRD | Director/Board Member | 52 | 31/05/08 |
Zehyon Paku
CTO | Chief Tech/Sci/R&D Officer | 48 | 30/06/17 |
Hatsuo Kato
CHM | Chairman | 80 | 31/05/20 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 01/05/24 | 18 | +5.88% | 4,625,500 |
| 30/04/24 | 17 | 0.00% | 2,162,000 |
| 26/04/24 | 17 | -5.56% | 5,666,000 |
| 25/04/24 | 18 | -5.26% | 3,194,200 |
| 24/04/24 | 19 | 0.00% | 2,604,900 |
Delayed Quote Japan Exchange, May 01, 2024 at 07:00 am
More quotes
OncoTherapy Science, Inc. is a Japan-based company mainly engaged in the development of drugs. The Company is involved in the development of low molecular drugs, antibody drugs and other drugs, as well as the provision and clinical development of medical candidate substances. The Company operates its business in cooperation with universities and other corporations. The Company provides its licenses to pharmaceutical manufacturers. The Company also involves in T Cell Receptor(TCR) analysis business.
Calendar
01/08/2024
- Q1 2025 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -21.74% | 23.5M | |
| -1.17% | 102B | |
| +2.87% | 96.09B | |
| +2.13% | 22.28B | |
| -14.77% | 21.4B | |
| -8.79% | 18.14B | |
| -39.98% | 17.02B | |
| -13.21% | 16.09B | |
| +8.55% | 13.83B | |
| +35.75% | 11.97B |
- Stock Market
- Equities
- 4564 Stock
